Novo Nordisk A's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Novo Nordisk A (NVO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Novo Nordisk A vs Its Competitors
- TTM: Trailing 12-month revenue of 46,820M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+5.7% annualized vs trailing 12 months).
- Scale: Novo Nordisk A ranks #8 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 3.2% of industry market cap.
- Peer revenue share: Novo Nordisk A accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
NVO Sales vs. its Competitors, Q4 2025
Novo Nordisk A generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.1% year over year, combined, vs 0.7% for Novo Nordisk A. Novo Nordisk A's share of combined industry revenue moved from 2.60% to 2.40%, a loss of 0.20 percentage points.
Novo Nordisk A's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Novo Nordisk A | Yes | Yes | Yes | No |
| High-Confidence Competitors (29) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 100.00 % (7 of 7) | 100.00 % (8 of 8) | 87.50 % (7 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
NVO Stock Performance relative to its Competitors
NVO Stock Performance relative to High-Confidence Competitors
NVO Stock Performance relative to Similar-Size Competitors
NVO Stock Performance relative to Similar Growth & Profitability Competitors
Novo Nordisk A's Comment on Competition and Industry Peers
Novo Nordisk A's Competitors Named by the Company
Competitive relationships identified from Novo Nordisk A reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Agentix Corp | Company report | 85% |
| Septerna Inc | Company report | 85% |
| Inventiva S a | Company report | 85% |
| Crispr Therapeutics Ag | Company report | 85% |
| Protagonist Therapeutics inc | Company report | 85% |
| Sagimet Biosciences inc | Company report | 85% |
| Embecta Corp | Company report | 85% |
| Altimmune inc | Company report | 85% |
| Dariohealth Corp | Company report | 85% |
| Palatin Technologies Inc | Company report | 85% |
| Corbus Pharmaceuticals Holdings Inc | Company report | 85% |
| Eli Lilly | Company report | 85% |
| Intellia Therapeutics Inc | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Alnylam Pharmaceuticals Inc | Company report | 85% |
| Skye Bioscience Inc | Company report | 85% |
| Lumos Pharma Inc | Company report | 85% |
| Biorestorative Therapies Inc | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Xeris Biopharma Holdings Inc | Company report | 85% |
| Mannkind Corporation | Company report | 85% |
| Agios Pharmaceuticals Inc | Company report | 85% |
| Lineage Cell Therapeutics Inc | Company report | 85% |
| Better Therapeutics Inc | Company report | 85% |
| Uniqure N v | Company report | 85% |
| Gyre Therapeutics Inc | Company report | 85% |
| IMAB | Company report | 85% |
| Novabridge Biosciences | Company report | 85% |
Company report basis, confidence, active dates and source counts for Novo Nordisk A's named competitors require a Commercial License.
Methodology: relationships are extracted from Novo Nordisk A reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.